Xinnate

Executive Summary

Xinnate is a private Swedish biotechnology company founded in 2019 and based in Gothenburg, focusing on RNA and gene therapy for inflammatory skin disorders. The company's lead candidate, TCP-25, is a first-in-class immunomodulatory peptide derived from thrombin, discovered by Professor Arthur Schmidtchen at Lund University. TCP-25 works by rebalancing the immune response, offering a novel therapeutic approach for conditions such as atopic dermatitis and other complex skin disorders. Preclinical studies have demonstrated its ability to dampen excessive inflammation while preserving normal immune function, positioning it as a potential alternative to conventional immunosuppressants. Xinnate is currently in the early stages of clinical development, with ongoing efforts to advance TCP-25 through Phase 1/2 trials. The company operates in a competitive landscape but differentiates itself through a unique mechanism of action derived from endogenous peptides. As a private entity, Xinnate may seek additional funding to support its pipeline and clinical programs, with upcoming milestones including trial readouts and potential regulatory designations.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 2 clinical trial for TCP-25 in atopic dermatitis60% success
• H2 2026Completion of Series A financing round to fund clinical development70% success
• Q3 2026Receipt of Orphan Drug Designation from FDA for TCP-2550% success